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In his commentary, Dr. Ola Saugstad tries to convince 
the readers of the journal that the replacement of acetyl-
salicylic acid with acetaminophen in the early 1980s has 
resulted in a sharp increase in autism spectrum disorder 
(ASD) in the USA. As a consequence, he warns against 
the use of prenatal and postnatal acetaminophen in preg-
nant women and their fetuses/neonates until we know 
more about a possible time period during the fetal/neo-
natal development where the developing brain might be 
more sensitive to potential side effects of acetaminophen 
and its metabolites [1]. He furthermore states that more 
care is needed when administering this “potentially toxic 
substance to individuals with developing brains.” He fin-
ishes his commentary by advocating for proper follow-up 
if using acetaminophen in newborns and infants to detect 
potential long-term adverse effects.
We would like to discuss in this commentary the argu-
ments Dr. Saugstad has used to reach the aforementioned 
conclusions and warnings, and at the end we would like 
to share with you our overall thoughts on this important 
topic.
Forty years ago, a link between the use of acetylsali-
cylic acid and Reye’s syndrome [2] resulted in a substitu-
tion across the globe of acetylsalicylic acid with acetamin-
ophen or ibuprofen. Some countries decided in favor of 
acetaminophen as replacement of acetylsalicylic acid 
whereas others preferred ibuprofen. There was not much 
rationale behind the choice of different countries to 
switch to either acetaminophen or ibuprofen.
Therefore, the fact that from 1970 to 2005 a sharp in-
crease in autism in the USA was observed does not auto-
matically seem to be linked to an increased use of acet-
aminophen as a replacement of acetylsalicylic acid world-
wide because clearly there was an equal division between 
countries who switched to acetaminophen versus ibupro-
fen. Moreover, in the USA, the predominant switch was 
from acetylsalicylic acid to ibuprofen, whereas in many 
European countries acetaminophen became the pre-
ferred drug.
ASD is a neurodevelopmental disorder characterized 
by varying deficits in social interactions, disordered com-
munication, and repetitive behavior patterns [3]. Signs 
that a child has autism are present in the early develop-
mental stages and the symptoms cause significant impair-
ment in many areas of functioning, including social, edu-
cational/occupational, and performance of everyday ac-
tivities. It has been shown that more than half of ASD 
cases are attributable to environmental factors. The use of 
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medications, cigarettes, later gestational age at the start of 
prenatal vitamins have all been correlated with ASD di-
agnosis [4]. Consequently, the search for additional envi-
ronmental factors is very reasonable, but what about the 
potential mechanisms between exposure to acetamino-
phen and the development of ASD?
Ten years ago, Schultz hypothesized that disruption of 
the endocannabinoid system by acetaminophen might 
result in an increase in ASD, particularly in children with 
a decreased capacity to metabolize acetaminophen [5]. 
This hypothesis is further supported by animal experi-
mental observations. Paracetamol drug metabolism re-
sults in p-aminophenol, a metabolite that interacts with 
cannabinoid receptors. Related to this, paracetamol and 
Δ(9)-tetrahydrocannabinol, but not ibuprofen, resulted 
in developmental neurotoxicity in a juvenile mice model 
[6–8]. Furthermore, co-administration of a cannabinoid 
receptor agonist enhanced the developmental neurotox-
icity of paracetamol [7]. 
The bulk of data in the human setting are observation-
al, based on epidemiological linkage between exposure 
and outcome, by definition hampered by the association 
between exposure and indication (acetaminophen intake 
because of pain or fever). Masarwa et al. [9] recently re-
ported in a systematic review on the link between prena-
tal paracetamol exposure and the risk for ADHD, ASD 
and hyperactivity, and suggested a pooled risk ratio of 
1.34 (95% CI 1.21–1.47), 1.19 (1.14–1.25) and 1.24 (1.04–
1.43), respectively, but acknowledged that these observa-
tional data remain susceptible to several sources of bias. 
This paper in the American Journal of Epidemiology re-
sulted in a fierce discussion between the authors of that 
paper and Damkier [10] underscoring that the issue of 
acetaminophen during pregnancy and childhood neuro-
development remains controversial and contested [11, 
12]. Masarwa and colleagues, in their response to the let-
ter to the editor of Damkier, wrote: “We share Damkier’s 
skepticism of the association between prenatal exposure 
to acetaminophen and neurodevelopmental outcomes, as 
well as his clinical concerns.” The latter part of this re-
sponse had to do with the fact that Masarwa et al. prema-
turely mentioned “recent alarming evidence on the tera-
togenicity of acetaminophen” in the same paper. The fact 
that this statement had no reference and was not sup-
ported by any evidence in their paper resulted in an ex-
ceptional and unnecessarily opinionated statement with 
substantial implications for health care professionals and 
pregnant women.
A very recent paper, published on January 1, 2020, sug-
gests the possibility that postnatal acetaminophen, mea-
sured in doses consumed before age 2, may be a signifi-
cant contributor to the risk of ASD among males in the 
US [13]. However, the real impact is unclear because oth-
er correlated variables were not included in the analysis. 
This paper also highlights the fact that we do not know 
much about the dose-concentration-effect relationship 
between exposure to acetaminophen and potential risk 
for ASD.
This automatically leads us to the paper of Ji et al. [14] 
who showed that kids with ASD as well as ADHD had 
higher concentrations of acetaminophen and its metabo-
lites in cord blood. The question is of course if just mea-
suring acetaminophen and its metabolites in cord blood 
and linking it to ASD/ADHD will help us explain the 
mechanism behind these findings. Is it the higher expo-
sure to acetaminophen and its metabolites that “causes” 
ASD/ADHD or is the fact that you are going to develop 
ASD/ADHD the reason why you have a different clear-
ance of acetaminophen? There is some evidence that sup-
ports the fact that kids with ASD/ADHD indeed have a 
different metabolism of acetaminophen and perhaps, as a 
consequence, have an elevated risk of adverse events if 
exposed to acetaminophen [15]. Furthermore, this design 
is also hampered because it was confounded by indication 
(maternal pain or fever during labor).
We would like to finish our commentary by applaud-
ing Dr. Saugstad for his provocative commentary that 
further underscores that we need to study childhood neu-
rodevelopment following in utero exposure to drugs [1]. 
However, the issue of acetaminophen use during preg-
nancy and childhood neurodevelopment remains con-
troversial and contested [11, 12]. A recent study by Ys-
trom et al. [16] reported comparable weak signals for the 
risk of ADHD following maternal in utero exposure and 
paternal acetaminophen exposure prior to conception. 
This very important point should force the epidemiolog-
ically minded community to revisit the issue of causality 
and confounding on this important matter. It will be im-
portant to prospectively investigate pregnant women and 
their fetuses/neonates who are exposed to acetamino-
phen with inclusion of as many covariates as feasible.
We would like to conclude that at this moment there 
is no reason to discontinue the use of acetaminophen in 
pregnant women and their neonates because the alterna-
tive, the use of opioids, has proven to result in a dramatic 
increase in opioid-addicted neonates across many coun-
tries worldwide, while exposure to other nonsteroidal an-
ti-inflammatory drugs like ibuprofen or indomethacin is 
associated with a much higher risk for fetal ductal closure 
when compared to acetaminophen [17].
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Lastly, we would like to advocate using appropriate 
dosing of acetaminophen in pregnant women and their 
newborns as we still consider this as a “real” drug with ef-
fects and potential side effects [18, 19]. This suggestion is 
in line with a recently revised summary of product char-
acteristics (the leaflet) for acetaminophen by the Euro-
pean Medicine Agency. The adapted wording (italics) 
reads “Epidemiological studies on neurodevelopment in 
children exposed to paracetamol in utero show inconclu-
sive results. If clinically needed, paracetamol can be used 
during pregnancy however it should be used at the lowest 
effective dose for the shortest possible time and at the 
lowest possible frequency” [20]. 
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